IL-7 Binding Proteins for Selective Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like multiple sclerosis are inadequate due to the role of IL-7 in maintaining pathogenic T cells, which contribute to inflammation and tissue damage, as existing therapies fail to effectively target the IL-7/IL-7R pathway.
Innovation Solution
Development of IL-7 binding proteins, such as antibodies or antigen binding fragments, that specifically bind to IL-7, inhibiting its interaction with the IL-7 receptor, thereby reducing IL-7 mediated signaling and cytokine production in T cells, while sparing regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat autoimmune diseases, then general immune suppression may occur, but pathogenic T cells are not effectively targeted and disease progression continues
Solution Approach 1:
The patent uses an antibody as an intermediary molecule that specifically binds to IL-7, preventing it from interacting with the IL-7 receptor on pathogenic T cells. This intermediary approach allows selective targeting of the IL-7/IL-7R pathway without broad immune suppression, thereby effectively reducing inflammation and tissue damage while improving treatment reliability for autoimmune diseases
Solution Approach 2:
The invention applies local quality by creating a therapy that specifically targets the IL-7 signaling pathway in pathogenic T cells rather than suppressing the entire immune system. The antibody selectively interferes with IL-7 binding at the molecular level, providing localized intervention that distinguishes between pathogenic and regulatory T cell functions, thus improving effectiveness without causing harmful broad immune suppression
2Reliability
If IL-7 binding proteins are developed to specifically inhibit IL-7/IL-7R pathway, then pathogenic T cell activity is reduced, but regulatory T cell function must be preserved
Solution Approach 1:
The antibody exhibits local quality by selectively targeting the IL-7/IL-7R interaction in pathogenic T cells while leaving regulatory T cell functions intact. This selective mechanism achieves high reliability in distinguishing between pathogenic and regulatory T cells, allowing the therapy to adapt to different T cell subsets without compromising regulatory functions
Solution Approach 2:
The invention utilizes parameter changes by modifying the binding characteristics of the antibody to specifically recognize and bind IL-7 with high affinity, thereby changing the equilibrium of IL-7 availability to pathogenic versus regulatory T cells. This parameter-based selectivity ensures that pathogenic T cell activity is reduced while regulatory T cell function is preserved, addressing both reliability and adaptability requirements
Data Source
AI summary
Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.